Cyxone's drug candidate T20K shows low oral toxicity

Cyxone announce that T20K demonstrates no measurable toxic effect in mice after oral administration of up to 100 mg/kg in a single dose.  Even at an oral dose of 250 mg/kg, half of the animals recovered well after treatment. Low toxicity of injected T20K has previously been reported by Cyxone.

Data from the toxicity study, in animals, show there is a large interval between the effective dose and the dose that can cause toxic effects.

Cyxone's CEO remarks: "The results of the toxicity studies show that T20K has the potential to be a drug for the treatment of Multiple Sclerosis with minimal side effects. These results will be used to help design a preclinical development program that, after approval by a regulatory body, will enable clinical trials to be initiated in 2018 ".

2016-12-19

Contact
Cyxone AB (publ)
Kjell G. Stenberg,
CEO Tel: 070-716 80 09
E-mail: kjell.g.stenberg@cyxone.com
Adelgatan 21
221 22 Malmö
www.cyxone.com 

This is information which Cyxone AB is required to publish under the EU Market Abuse Regulation. The information was provided by the auspices of the above contact person for publication on December 19, 2016 at. 09:25 CET.

About Cyxone
Cyxone AB (publ) is a biopharmaceutical company developing drugs based on cyclotides, a class of natural plant proteins. Cyclotide technology has the potential to provide new drugs offering beneficial pharmacological effects for diseases that currently lack effective and safe treatments. The company is focusing on the development of T20K, a substance which inhibits key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxones Certified Adviser on Nasdaq First North is Erik Penser Bank.